Aligos Therapeutics, Inc. (ALGS) Fair Value 2026

ALGS · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.9 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (45/100)

Quick Summary — As of 2026-08-28, Aligos Therapeutics, Inc. (ALGS) trades at $6.91. QOC: 4.9/10. Value Trap Risk: 45/100 (WARN). 1/13 models active.

Key Facts

Ticker
ALGS
Price
$6.91
Quality Score
4.9/10
Value Trap Risk
45/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Value Trap score of 45 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give ALGS?

1 Intrinsic Value Models vs. Current Price ($6.91)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.20 -97.2%

All Models Active

All 1 models are displayed above.

What Is Aligos Therapeutics, Inc. (ALGS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Aligos Therapeutics, Inc.'s intrinsic value is estimated at $0.20, suggesting the stock is overvalued at its current price of $6.91. With 1 out of 1 models flagging downside (-97.2% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About ALGS?

1 of 13 models are currently active for ALGS. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does ALGS Rank in Biotechnology?

Among 625 Biotechnology stocks, ALGS ranks #337 by Quality of Company score. CirclFi's QOC score of 4.9/10 evaluates 32 fundamental signals. A score of 4.9 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, Aligos Therapeutics, Inc. operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating ALGS should weigh these sector-specific dynamics alongside our model-derived fair values.

Is ALGS a Value Trap?

CirclFi's Value Trap algorithm assigns ALGS a score of 45/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Aligos Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Aligos Therapeutics, Inc.'s fundamental quality profile registers 4.9/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ALGS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ALGS's 1 active models, average confidence is 59%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Aligos Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

CURXCuranex Pharmaceuticals IncQOC 4.9CGEMCullinan Therapeutics, Inc.QOC 4.9VTVTvTv Therapeutics Inc.QOC 4.9SRZNSurrozen, Inc.QOC 4.9ARTVArtiva Biotherapeutics, Inc.QOC 4.9ANROAlto Neuroscience, Inc.QOC 4.9FBRXForte Biosciences, Inc.QOC 4.3MNKDMannKind CorporationQOC 8.3OABIOmniAb, Inc.QOC 5.7EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: CURX · CGEM · VTVT · SRZN · ARTV · ANRO · FBRX · MNKD · OABI · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ALGS?

4 companies across all industries closest to ALGS’s Quality of Company score of 4.9/10.

CLMTCalumet, Inc.QOC 4.9PSQHPSQ Holdings, Inc.QOC 4.9TRONTron Inc.QOC 4.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CLMT · PSQH · TRON · NVDA

Where Does ALGS Sit in CirclFi's Biotechnology Rankings?

ALGS is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Aligos Therapeutics, Inc.’s Valuation?

What is Aligos Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Aligos Therapeutics, Inc. (ALGS). The Quality of Company score is 4.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ALGS overvalued or undervalued right now?

At $6.91, 0 of 1 active models suggest ALGS may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Aligos Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.9 mean for ALGS?

Aligos Therapeutics, Inc.'s QOC of 4.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on ALGS?

CirclFi analyzes ALGS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is ALGS a value trap in 2026?

Aligos Therapeutics, Inc.'s Value Trap score is 45/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Aligos Therapeutics, Inc. (ALGS) a Quality of Company score of 4.9/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/ALGS/ · Methodology
Primary sources for this ALGS valuation
  • Financial statements: Aligos Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001799448) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ALGS as of ; valuations recomputed .